TARGET BP I Clinical Trial

Inclusion Criteria:

   1. Has 3 office blood pressure measurements with a mean office systolic blood pressure
   (SBP) of ≥150 mmHg and ≤180 mmHg, AND a mean office diastolic blood pressure (DBP) of
   ≥90 mmHg when receiving 2 to 5 antihypertensive medications.

   2. Has a mean 24-hour ambulatory SBP of ≥135 mmHg and ≤170 mmHg with ≥70% valid readings

Exclusion Criteria:

   1. Subject has renal artery anatomy abnormalities.

   2. Subject has an estimated glomerular filtration rate (eGFR) of ≤45 mL/min/1.73 m2,
   based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation; or
   is on chronic renal replacement therapy.

   3. Subject has documented sleep apnea.

   4. Subject has any of the following conditions: severe cardiac valve stenosis, heart
   failure (New York Heart Association [NYHA] Class III or IV), chronic atrial
   fibrillation, and known primary pulmonary hypertension (>60 mmHg pulmonary artery or
   right ventricular systolic pressure).

   5. Subject is pregnant or lactating at the time of enrollment or planning to become
   pregnant during the trial time period (female subjects only).

   6. Subject is being treated chronically (e.g. daily use) with NSAIDs, immunosuppressive
   medications, or immunosuppressive doses of steroids. Aspirin therapy and nasal
   pulmonary inhalants are allowed.

   7. Subject has a history of myocardial infarction, unstable angina pectoris, or
   stroke/TIA within 6 months prior to the planned procedure.